Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 51-54

  Sasaki, Hidefumi ^a   Shimizu, Shigeki ^b   Tani, Yoichi ^c   Shitara, Masayuki ^a   Okuda, Katsuhiro ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c Dako Japan Inc   (Japan)

Author keywords

599 insertion T; BRAF; EnVision; IHC; Linker; Lung adenocarcinoma; V600E expression

Indexed keywords

ANTIBODY; B RAF KINASE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL ARTICLE; CLONE; FEMALE; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; LUNG ADENOCARCINOMA; MALE; MUTANT; PRIORITY JOURNAL; WILD TYPE;

599 INSERTION T; BRAF; ENVISION; IHC; LINKER; LUNG ADENOCARCINOMA; V600E EXPRESSION;

ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; LUNG NEOPLASMS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY;

EID: 84884413617     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.014     Document Type: Article

References (25)

1. Ginsberg R.J., Kris K., Armstrong G. Cancer of the lung. Principles and practice of oncology 1993, 673-682. Lippincott, Philadelphia. 4th ed.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Sasaki H., Shimizu S., Endo K., Takada M., Kawahara M., Tanaka H., et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006, 118:180-184.
5. Fukuoka M., Wu Y.-L., Thongprasert S., Sunpaweravong P., Leong S.-S., Sriuranpong V., et al. Biomarker analyses and first overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
6. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
7. Peyssonnaux C., Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93:53-62.
8. Brose M.S., Voipe P., Feldman M., Kumar M., Rishi I., Gerrero R., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
9. Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62:7001-7003.
10. Sasaki H., Kawano O., Endo K., Suzuki E., Haneda H., Yukiue H., et al. Uncommon V599E Braf mutations in Japanese patients with lung cancer. J Surg Res 2006, 133:203-206.
11. Paik P.K., Arcila M.A., Fara M., Sima C.S., Miller V.A., Kris M.G., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2051.
12. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
13. Arkenau H.T., Kefford R., Long G.V. Targeting BRAF for patients with melanoma. Br J Cancer 2011, 104:392-398.
14. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
15. Capper D., Preusser M., Habel A., Sahm F., Ackemann U., Schinder G., et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011, 122:11-19.
16. Capper D., Berghoff A.S., Magerle M., Ilhan A., Wohrer A., Hackl M., et al. Immunohistochemical testing of BRAF V600E status in 1120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012, 123:223-233.
17. Sasaki H., Shitara M., Yokota K., Okuda K., Hikosaka Y., Moriyama S., et al. Braf and erbB2 mutations correlate with smoking status in lung cancer patients. Exp Ther Med 2012, 3:771-775.
18. Sasaki H., Okuda K., Kawano O., Endo K., Yukiue H., Yokoyama T., et al. Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep 2007, 18:623-628.
19. Yokota K., Sasaki H., Okuda K., Shimizu S., Shitara M., Hikosaka Y., et al. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep 2012, 28:1187-1192.
20. Ilie M., Long E., Hofman V., Dadone B., Marquette C.H., Mouroux J., et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013, 24:742-748.
21. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2012, 380:358-365.
22. Eisenhardt A.E., Olbrich H., Roring M., Janzarik W., Van Anh T.N., Cin H., et al. Functional characterization of a BRAF insertion mutation associated with pilocytic astrocytoma. Int J Cancer 2011, 129:2297-2303.
23. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy B.R., Costa B.R., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
24. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
25. Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J., et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010, 16:1561-1571.